We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

YM598 in Patients With Rising PSA After Initial Therapy for Localized Prostate Cancer

This study has been terminated.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00050297
First Posted: December 4, 2002
Last Update Posted: June 7, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Astellas Pharma US, Inc.
Information provided by:
Astellas Pharma Inc
December 3, 2002
December 4, 2002
June 7, 2012
Not Provided
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00050297 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
YM598 in Patients With Rising PSA After Initial Therapy for Localized Prostate Cancer
Not Provided
The purpose of this study is to determine the optimal dosage of YM598 for slowing down disease progression in patients with rising PSA after initial therapy for localized prostate cancer.
Not Provided
Interventional
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Prostate Cancer
Drug: YM598
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
Not Provided
February 2004
Not Provided
Not Provided
Sexes Eligible for Study: Male
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Belgium,   Czech Republic,   France,   Germany,   Poland,   Spain,   United Kingdom
 
 
NCT00050297
598-CL-004
Not Provided
Not Provided
Not Provided
Not Provided
Astellas Pharma Inc
Astellas Pharma US, Inc.
Not Provided
Astellas Pharma Inc
June 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP